

## NEURO-IMMUNOLOGY

Saturday, March 28, 2020

<b>07:30-08:30</b>	<b>E-Poster Presentations (Exhibition Area)</b>
<b>08:30-10:10</b>	<b>QUESTIONABLE AUTOIMMUNE DISEASES</b>
Chairs:	<b>Rina Aharoni</b> , Israel   <b>Jacob Saiju</b> , UK
<b>08:30-09:20</b>	<b>PANDAS is a clinically distinct entity and needs early and prompt immunotherapy.</b> <i>Capsule: The nosology of pediatric acute neuropsychiatric syndromes like PANDAS remains controversial, and the evidence for immunopathology and in particular autoimmunity driven by streptococcal infection is still being questioned. Is PANDAS a distinct disorder and is prompt immunotherapy indicated for treatment?</i>
08:30-08:40	Host: <b>Alicja Kalinowska</b> , Poland
08:40-08:55	Yes: <b>Ronny Wickström</b> , Sweden
08:55-09:10	No: <b>Ming Lim</b> , UK
09:10-09:20	Discussion and rebuttals
<b>09:20-10:10</b>	<b>Is narcolepsy an autoimmune disorder which should be treated as such?</b>
09:20-09:30	Host: <b>Friedemann Paul</b> , Germany
09:30-09:45	Yes: <b>Jacek Losy</b> , Poland
09:45-10:00	No: <b>Angela Vincent</b> , UK
10:00-10:10	Discussion and rebuttals
<b>10:10-10:25</b>	<b>Coffee Break</b>
<b>10:25-12:05</b>	<b>NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) TREATMENT</b>
Chairs:	<b>Eduardo Gomez-Utrero</b> , Spain
<b>10:25-11:15</b>	<b>New regulatory-approved medications should be used exclusively for prevention of attacks of NMOSD over currently used non-regulatory approved medications.</b> <i>Capsule: It is likely that 3 immunomodulatory treatments, a C5 complement inhibitor, an anti-CD19 monoclonal antibody and an inhibitor of IL6 receptor, will all receive regulatory approval for treatment of NMOSD. Do these drugs offer sufficient advantages that they should replace currently used immunotherapies that are widely regarded as effective and are less expensive?</i>
10:25-10:35	Host: <b>Brian Weinschenker</b> , USA
10:35-10:50	Yes: <b>Friedemann Paul</b> , Germany
10:50-11:05	No: <b>Andrzej Glabinski</b> , Poland
11:05-11:15	Discussion and rebuttals
<b>11:15-12:05</b>	<b>NMOSD attacks should be treated with apheresis/plasma exchange at first presentation, either with or without corticosteroids.</b> <i>Capsule: Recent experience suggests that concomitant or first line treatment with plasma exchange may be superior to first line treatment with corticosteroids. Is a change in the standard approach of using corticosteroids first appropriate given the current state of knowledge?</i>
11:15-11:25	Host: <b>Bruno Gran</b> , UK
11:25-11:40	Yes: <b>Ingo Kleiter</b> , Germany
11:40-11:55	Steroids should be used first: <b>Maria Isabel Leite</b> , UK
11:55-12:05	Discussion and rebuttals
<b>12:05-12:15</b>	<b>Short Break</b>
<b>12:15-13:15</b>	<b>Industry Symposium</b>
<b>13:15-14:15</b>	<b>Lunch Break</b>
<b>13:15-14:15</b>	<b>Meet the Expert</b>
<b>14:45-15:45</b>	<b>NMOSD AND CIDP</b>
Chairs:	
<b>14:15-15:00</b>	<b>The 2015 International Panel criteria for NMOSD are outdated and should be replaced with a diagnostic classification based on autoantibody status rather than clinical presentation (i.e. AQP4 disease, MOG disease).</b> <i>Capsule: We now know the molecular target of the autoimmune insult in the majority of patients with NMOSD, and molecular classification based on the target of the antibody can be used in lieu of clinical criteria for diagnosis of what we currently refer to as NMOSD. Are we ready for a molecular classification of NMOSD in 2020?</i>

14:15-14:25 Host: **Jacek Losy**, Poland  
14:25-14:40 Yes: **Angela Vincent**, UK  
14:40-14:55 No: **Ingo Kleiter**, Germany  
14:55-15:00 Discussion and rebuttals

**15:00-15:45 Treatment of CIDP - immunoglobulins or steroids first?**

*Capsule: Many treatments have been advocated for CIDP, but the best accepted options are intravenous immunoglobulin and corticosteroids. Which treatment is best and should be applied first?*

15:00-15:10 Host: **Joab Chapman**, Israel  
15:10-15:25 Immunoglobulins: **Marinos Dalakas**, USA  
15:25-15:40 Steroids: **Eduardo Nobile-Orazio**, Italy  
15:40-15:45 Discussion and rebuttals

**15:45-16:00 Coffee Break**